Glucotrack, Inc. filed an amended 8-K to update the terms of a material definitive agreement entered into on July 24, 2026. The company partitioned a new promissory note with an original principal amount of $900,000 from an existing debt instrument held by an investor. This partition reduced the outstanding balance of the original note. Under the exchange agreement, the investor may convert portions of this $900,000 note into shares of common stock at a price based on recent Nasdaq closing prices. The conversion is subject to a 9.99% beneficial ownership limitation and requires share delivery by August 31, 2026. Glucotrack, Inc. operates in the healthcare technology industry, developing non-invasive glucose monitoring systems.

Glucotrack, Inc. entered into an Exchange Agreement on July 22, 2026, to partition a new $900,000 promissory note from an existing debt obligation. The agreement allows the investor to exchange the partitioned note for common stock at a price based on the lower of the Nasdaq closing price or a five-day average. The transaction involves no cash consideration and is subject to a 9.99% beneficial ownership limitation. Glucotrack, Inc. develops medical technology for glucose monitoring and metabolic health management.

Glucotrack, Inc. completed a strategic business combination with Lōkahi Therapeutics, Inc. on July 14, 2026. Under the merger agreement, Lōkahi Therapeutics becomes the controlling business, with its securityholders expected to hold approximately 90.0% of the combined company on a fully diluted basis through a combination of common stock and Series A convertible preferred stock. Erik Emerson was appointed Chief Executive Officer, replacing Paul V. Goode, who will serve as Chief Technical Officer and CEO of the Glucotrack continuous blood glucose monitoring subsidiary. The transaction includes a planned private placement of up to $30,000,000 and a $4.45 million bridge financing. Glucotrack, Inc. is a medical technology company focused on developing continuous blood glucose monitoring systems for diabetes management.